The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Enhanced Delivery of Doxorubicin into the Brain via a Peptide-Vector-Mediated Strategy: Saturation Kinetics and Specificity
Abstract
Doxorubicin delivery to the brain is often restricted because of the poor transport of this therapeutic molecule through the blood-brain barrier (BBB). To overcome this problem, we have recently developed a technology, Pep:trans, based on short natural-derived peptides that are able to cross efficiently the BBB without compromising its integrity. In this study, we have used the in situ mouse brain perfusion method to evaluate the brain uptake of free and vectorized doxorubicin. Doxorubicin was coupled covalently to small peptide vectors: L-SynB1 (18 amino acids), L-SynB3 (10 amino acids), and its enantio form D-SynB3. We first confirmed the very low brain uptake of free radiolabeled doxorubicin, which is most likely due to the efflux activity of the P-glycoprotein at the level of the BBB. Vectorization with either L-SynB1, L-SynB3, or D-SynB3 significantly increased the brain uptake of doxorubicin (about 30-fold). We also investigated the mechanism of transport of vectorized doxorubicin. We show that vectorized doxorubicin uses a saturable transport mechanism to cross the BBB. The effect of poly(L-lysine) and protamine, endocytosis inhibitors, on the transport across the brain was also investigated. Both inhibitors reduced the brain uptake of vectorized doxorubicin in a dose-dependent manner. These studies indicate that the transport of vectorized doxorubicin appears to occur via an adsorptive-mediated endocytosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olivier, J.-C., Fenart, L., Chauvet, R., Pariat, C., Cecchelli, R., & Couet, W. (1999) · Pharmaceutical Research · doi:10.1023/a:1018947208597 · Cited by 213
Cited by
Twenty years of cell‐penetrating peptides: from molecular mechanisms to therapeutics
Heitz, F., Morris, M. C., & Divita, G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00057.x · Cited by 867
Cell-penetrating peptides: classes, origin, and current landscape
Milletti, F. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.03.002 · Cited by 813
CNS Delivery Via Adsorptive Transcytosis
Hervé, F., Ghinea, N., & Scherrmann, J.-M. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9055-2 · Cited by 676
Self-citationStudies on the Internalization Mechanism of Cationic Cell-penetrating Peptides
Drin, G., Cottin, S., Blanc, E., Rees, A. R., & Temsamani, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303938200 · Cited by 530
Self-citationNanoparticles and targeted drug delivery in cancer therapy
Bahrami, B., Hojjat-Farsangi, M., Mohammadi, H., Anvari, E., Ghalamfarsa, G., Yousefi, M., & Jadidi-Niaragh, F. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.07.015 · Cited by 510
Metadata
- Authors
- Rousselle, C., Smirnova, M., Clair, P., Lefauconnier, J.-M., Chavanieu, A., Calas, B., Scherrmann, J.-M., & Temsamani, J.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2001-01
- Volume
- 296
- Issue
- 1
- Pages
- 124-131
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2294465180
- Cited by
- 159
- References
- 1
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhanced Delivery of Doxorubicin into the Brain via a Peptide-Vector-Mediated Strategy: Saturation Kinetics and Specificity. https://app.cochat.ai/papers/10.1016/s0022-3565(24)29672-5
- The paper
- Rousselle, C., Smirnova, M., Clair, P., Lefauconnier, J.-M., Chavanieu, A., Calas, B., Scherrmann, J.-M., & Temsamani, J. (2001). Enhanced Delivery of Doxorubicin into the Brain via a Peptide-Vector-Mediated Strategy: Saturation Kinetics and Specificity. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/s0022-3565(24)29672-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.